Filing Flows

Filing Flows › Health Care › Vistagen Therapeutics (VTGN)

Vistagen Therapeutics (VTGN) earnings and revenue breakdown

Latest: Q1 FY27 · 10-Q filed Aug 14, 2026 · Vistagen Therapeutics (VTGN) Q1 FY27 earnings results →

Q1 FY27 Revenue up 505% year over year to $1.5M · 883¢ of every $1 of revenue lost · operating margin -904.3%

Vistagen Therapeutics made $1.5M in Q1 FY27 (+505% Y/Y). Operating margin -904.3%, net loss $13.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.

Revenue$1.5M
Year over year+505%
Operating margin-904.3%
Net earnings−$13.0M
Operating cash flow−$14.7M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $1.5M in Q1 FY27, up 505% year over year and up 217% from the previous quarter.

Operating costs exceeded revenue by $13.3M, an operating margin of -904.3%. Total costs fell 8% while revenue rose 505%. The quarter ended with a net loss of $13.0M, narrower than the previous quarter's $16.3M loss.

Operating cash flow was −$14.7M. Non-cash charges added back $52K of depreciation and amortization and $1.0M of share-based compensation. Working capital and other items used $2.7M.

Quarterly history

Vistagen Therapeutics revenue by quarterVistagen Therapeutics revenue by quarter$234KQ3 FY25$244KQ1 FY26$258KQ2 FY26$303KQ3 FY26$465KQ4 FY26$1.5MQ1 FY27
Vistagen Therapeutics net earnings by quarterVistagen Therapeutics net earnings by quarter−$14.1MQ3 FY25−$15.1MQ1 FY26−$19.4MQ2 FY26−$18.9MQ3 FY26−$16.3MQ4 FY26−$13.0MQ1 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q1 FY2710-QAug 14, 2026$1.5M+505%-904.3%−$13.0M−$14.7M
Q4 FY2610-KJun 15, 2026$465K—n/m−$16.3M−$16.2M
Q3 FY2610-QFeb 12, 2026$303K+30%n/m−$18.9M−$17.6M
Q2 FY2610-QNov 13, 2025$258K+41%n/m−$19.4M−$13.8M
Q1 FY2610-QAug 7, 2025$244K+190%n/m−$15.1M−$18.8M
Q3 FY2510-QFeb 13, 2025$234K-43%n/m−$14.1M−$10.3M

Charts

Vistagen Therapeutics: revenue growth, year over year and quarter over quarterVistagen Therapeutics: revenue growth, year over year and quarter over quarterY/YQ/Q-43%Q3 FY25+190%+4%Q1 FY26+41%+6%Q2 FY26+30%+17%Q3 FY26+53%Q4 FY26+400%+217%Q1 FY27
Latest (Q1 FY27): Y/Y +400%, Q/Q +217%.
Vistagen Therapeutics: where the cash came from (+) and went (−), TTM to Q1 FY27Vistagen Therapeutics: where the cash came from (+) and went (−), TTM to Q1 FY27Operating cash flow−$62.3MCash drawn (+) / kept (−)$32.0MOther financing$31.3MNet borrowing (+) / repaid (−)−$931KOther investing−$89K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Vistagen Therapeutics: profit against cash, quarter by quarterVistagen Therapeutics: profit against cash, quarter by quarterNet incomeOperating cash flow−$13.0M−$10.9MQ2 FY25−$14.1M−$10.3MQ3 FY25−$13.6M−$10.1MQ4 FY25−$15.1M−$18.8MQ1 FY26−$19.4M−$13.8MQ2 FY26−$18.9M−$17.6MQ3 FY26−$16.3M−$16.2MQ4 FY26−$13.0M−$14.7MQ1 FY27
Latest (Q1 FY27): Net income −$13.0M, Operating cash flow −$14.7M.
Vistagen Therapeutics: diluted shares by fiscal year (split-adjusted)Vistagen Therapeutics: diluted shares by fiscal year (split-adjusted)258MFY2121MFY2319MFY2431MFY2538MFY26
-85.3% since FY21: buybacks shrank the count; earlier years scaled for the 3-for-1 split before FY24.
Vistagen Therapeutics in its industry: growth against margin (225 companies, SIC 2834)Vistagen Therapeutics in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMVTGN (+300%, -100%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Vistagen Therapeutics

We are a late clinical-stage therapeutics company focused on developing and potentially commercializing new medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. Each of the five clinical-stage intranasal pherine product candidates in our neuroscience pipeline has a novel neurocircuitry-focused proposed mechanism of action (MOA) and at least one positive clinical study in its targeted patient population.

In its own words, from its 10-K, filed Jun 15, 2026.

Vistagen Therapeutics against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +505% against the peers' median +10%. Operating margin: -904.3% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
VTGN Vistagen TherapeuticsQ1 FY27$1.5M+505%-904.3%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Vistagen Therapeutics 10-Q on SEC EDGAR · CIK 1411685 · Pharmaceutical Preparations

13F: who owns VTGN and who is buying

Largest holders of VTGN (13F)Largest holders of VTGN (13F)Vanguard Group$1.2MCommodore Capital LP$630KVanguard Capital Management LLC$356KTwo Sigma Investments, LP$192KAcadian Asset Management LLC$178KRenaissance Technologies LLC$165KCubist Systematic Strategies, LLC$156KIkarian Capital, LLC$117KAdvisorShares Investments LLC$99KLuminus Management LLC$91K
Funds' net buying of VTGN by quarter (13F)Funds' net buying of VTGN by quarter (13F)$954K2024-09−$9.2M2024-12$1.1M2025-03−$889K2025-06$30.6M2025-09−$6.4M2025-12$932K2026-03−$809K2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on VTGN

History

Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q3 FY25 results

Compare VTGN with

中文版：Vistagen Therapeutics（VTGN）财报

Español · Français